drugset / Trial / NCT04912856
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Non-randomizedSequentialQuadruple-blindTreatment
Summary
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).
Timeline
- Start
- 2021-08-17
- Primary completion
- 2023-11-17
- Completion
- 2023-11-17
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision; not a safety decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ezogabine | Small molecule | 21 mg/kg | Oral |
| Subject | Ezogabine | Small molecule | 672 mg | Oral |